Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
Sponsor: Arrowhead Pharmaceuticals
This PHASE1/PHASE2 trial investigates Diabetes Mellitus, Type 2 and Obesity and is currently actively recruiting participants. Arrowhead Pharmaceuticals leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arrowhead Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .